Abstract
This was a single-agent phase II clinicaltrial of the antifol piritrexim in patientswith advanced transitional cell carcinomaof the bladder.
Methods: Patientswith previously-treated, advancedurothelial carcinoma were treated with oralpiritrexim at a dose of 25 mg three timesdaily for 5 consecutive days each week for3 consecutive weeks followed by a 1-weekrest period. Courses were repeated every28 days.
Results: Thirty-fivepatients were enrolled in the study, with28 patients evaluable for survival andtoxicity and 27 evaluable for response.
Toxicity: Myelosuppression was themajor dose-limiting toxicity, with WHOgrade 3/4 thrombocytopenia in 4 patients,granulocytopenia in 1 patient, and anemiain 3 patients. Grade 3 nonhematologictoxicity consisted of neuropathy in 5patients, hepatotoxicity in 2, nausea in 2,and 1 each with pulmonary toxicity andrash.
Efficacy: Of the 27 patientsevaluable for response, 2 (7%) achieved anobjective response, lasting 112 and 142days, respectively.
Conclusion: Piritrexim has minimal activity in patientswith previously treated transitional cellcarcinoma of the bladder, regardless ofprior exposure to methotrexate, and furtherevaluation of this compound in thisclinical setting is not warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg L, Rosado K, Smart T, Lin S, Penenberg D, Fair WR, Whitmore WF: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64:2448–2458, 1989
Roth BJ, Bajorin DF: Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153:894–900, 1995
Witte RS, Elson P, Khandaker J, Trump DL: An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 73:688–691, 1994
Duch DS, Edelstein MP, Bowers SW: Biochemical and chemotherapeutic studies in 2,4-diamino-6(2,5-dimethoxybenzyl)5-methyl pyridio (2,3d) pyrimidine (BW 301u): a novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res 42:3987–3994, 1982
Sedwick WD, Hamrell, Brown DE: Metabolic inhibition by a new antifolate 2,4-diamino-6 (2,5 dimethoxybenzyl) 5-methyl-pyrido (2,3d) pyrimidine (BW301u), an effective inhibitor of human lymphoid and dehydrofolate reductase-over producing mouse cell lines. Mol Pharmacol 22:766–770, 1982
Weiss GR, Sarosy GA, Shenkenberg TD, Williams T, Clendeninn NJ, von Hoff DD, Woolley JL, Liao SHT, Blum MR: A phase I clinical and pharmacologic study of weekly intravenous infusions of piritrexim (BW301U). Eur J Cancer Clin Oncol 25:1867–1873, 1990
Feun LG, Savaraj N, Benedetto P, Hanlon J, Sridhar KS, Collier M, Richman S, Liao SH, Clendeninn NJ: Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. J Natl Cancer Inst 83:51–55, 1991
Feun LG, Gonzales R, Savaraj N, Hanlon J, Collier M, Robinson WA, Clendeninn NJ: Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. J Clin Oncol 9:464–467, 1991
Feun LG, Savaraj N, Benedetto P, Waldman S, Collier M, Clendennin NJ: Oral piritrexim in advanced bladder cancer: an effective drug after progression on M-VAC chemotherapy? Am J Clin Oncol (CCT) 17:448–451, 1994
de Wit R, Kaye SB, Roberts JT, Stoter G, Scott J, Verweij J: Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 67:388–390, 1993
Khorsand M, Lange J, Feun L, Clendeninn NJ, Collier M, Wilding G: Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs 15:157–163, 1997
De Lena M, Lorusso V, Amadori D, Antimi M, Gridelli C, Luporini G, Pollera C, Oliva C: Gemcitabine in resistant stage IV bladder cancer: a phase II study. Eur J Cancer 31A(Suppl 5):S240, 1995
Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441–3445, 1997
Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394–3398, 1997
Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (E1892). J Clin Oncol 12:2264–2270, 1994
Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, Armstead B, Fox K, Wein A: Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16:255–260, 1998
Redman BG, Smith DC, Flaherty L, Du W, Hussain M: Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844–1848, 1998
Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:2876–2881, 1999
Kaufman D, Raghavan D, Carducci M, Levine GE, Murphy BA, Aisner J, Kuzel T, Nicol S, Oh W, Stadler WM: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921–1927, 2000
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068–3077, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roth, B.J., Manola, J., Dreicer, R. et al. Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group. Invest New Drugs 20, 425–429 (2002). https://doi.org/10.1023/A:1020675017737
Issue Date:
DOI: https://doi.org/10.1023/A:1020675017737